Objectives: Prediction of histopathological response with PET/CT scans after neoadjuvant chemoradiotherapy is limited by confounding factors which have been evaluated in this analysis. Methods:18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/45 Gy). Results: Sixty patients [40 male/20 female, median age 56 years (34–78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected. Pathologic complete response of the primary tumor was observed in 19 patients (41%) with a broad range of SUVmean (0.4–9.8, mean 3.0) after neoadjuvant therapy. A high rate of histopathological complete remissions (44%) was observed in tumors with a postinduction SUV >2.5 and volumes larger than the median (7.9 cm3) before resection. SUVmean was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03). Conclusions: These observations suggest that postinduction FDG uptake should be interpreted with caution in larger residual tumor volumes, since high SUV levels may be due to macrophage infiltration and not viable tumor tissue.

Albain K, Rusch V, Crowley J, Rice T, Turrisi A, Weick J, Lonchyna V, Presant C, McKenna R, Gandara D, Fosmire H, Taylor S, Stelzer K, Beasley K, Livingston R: Long-term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805. Proc Am Soc Clin Oncol 1999;18:467.
Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622–634.
Grunenwald DH, Andre F, Le Pechoux C, Girard P, Lamer C, Laplanche A, Tarayre M, Arriagada R, Le Chevalier T: Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:796–802.
Stamatis G, Eberhardt W, Stüben G, Bildat S, Dahler O, Hillejan L: Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 1999;68:1144–1149.
Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ: FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179–187.
Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M: Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651–2657.
Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK: Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small lung cancer. Ann Thorac Surg 2004;77:254–259.
Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, Ginsberg RJ, Rusch VW, Larson SM: An initial experience with FDG-PET in the imaging of residual disease after induction chemotherapy for lung cancer. Ann Thorac Surg 2002;73:529–536.
Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR: Positron emission tomography scanning with 2-fluoro-2-deosy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003;125:938–944.
Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA: Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903–1909.
Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS: Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol2005;23:8362–8370.
Schmücking M, Baum RP, Bonnet R, Junker K, Müller KM: Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment. Pathologe 2005;26:178–190.
Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255–3260.
Choi NC, Fischman AJ, Niemierko A, Ryu JS, Lynch T, Wain J, Wright C, Fidias P, Mathisen D: Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;54:1024–1035.
Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA: 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776–1785.
Ohtsuka T, Nomori H, Watanabe K, Naruke T, Orikasa H, Yamazaki K, Suemasu K, Uno K: False-positive findings on [18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer. Jpn J Clin Oncol 2005;35:271–273.
Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M: Value of 18F-fluoro-2-deoxy- D-glucose-positron emission tomography/computed tomography in non small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97–106.
Beyer T, Townsend D: Dual-modality PET/CT acquisition systems for clinical oncology; in Oehr P, Biersack HJ, Coleman E (eds): PET and PET/CT in Clinical Oncology. Heidelberg, Springer, 2003, pp 9–28.
Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, Alavi A: Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nocules on FDG-PET. Eur J Nucl Med2002;29:1639–1647.
Junker K, Langner K, Klinke F, Bosse U, Thomas M: Grading of tumour regression in non-small cell lung cancer: morphology and prognosis. Chest 2001;120:1584–1591.
Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181.
SAS Institute Inc.: SAS/STAT User’s Guide, Version 6, ed 4. Cary, SAS Institute Inc., 1989.
Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, Ball DL: The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001;42:1605–1613.
Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285–1292.
Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK: FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005;63:1053–1059.
Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA: Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002;4:301–310.
Deichen JT, Prante O, Gack M, Schmiedehausen K, Kuwert T: Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med 2003;30:267–273.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T: Intratmoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972–1980.
Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, Mortelmans L, Vandenberghe P, De Wolf-Peeters C: [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682–688.
de Geus-Oei LF, van Krieken JHJM, Aliredjo RP, Krabbe PFM, Frielink C, Verhagen AFT, Boerman OC, Oyen WJG: Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79–87.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.